# Check for updates

### **OPEN ACCESS**

EDITED AND REVIEWED BY David Cameron Wraith, University of Birmingham, United Kingdom

\*CORRESPONDENCE Shengying Qin Chinsir@sjtu.edu.cn Luming Sun Uming\_sun@163.com

<sup>†</sup>These authors share first authorship

RECEIVED 21 May 2025 ACCEPTED 05 June 2025 PUBLISHED 23 June 2025

#### CITATION

Zhou X, Wang W, Chen L, Yang Y, Wei X, Zhou J, Sun K, Tang P, Sun X, Qin S and Sun L (2025) Correction: Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology. *Front. Immunol.* 16:1632381. doi: 10.3389/fimmu.2025.1632381

### COPYRIGHT

© 2025 Zhou, Wang, Chen, Yang, Wei, Zhou, Sun, Tang, Sun, Qin and Sun. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Correction: Investigation of potential protein biomarkers for the screening of placentalmediated fetal growth restriction disorders using targeted proteomics Olink technology

Xinyao Zhou<sup>1†</sup>, Wuqian Wang<sup>2,3†</sup>, Luan Chen<sup>3</sup>, Yingjun Yang<sup>4</sup>, Xing Wei<sup>1</sup>, Jia Zhou<sup>1</sup>, Kuan Sun<sup>1</sup>, Ping Tang<sup>5</sup>, Xiaofang Sun<sup>2</sup>, Shengying Qin<sup>3\*</sup> and Luming Sun<sup>4,6\*</sup>

<sup>1</sup>Department of Fetal Medicine & Prenatal Diagnosis Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China, <sup>2</sup>Department of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, <sup>3</sup>Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China, <sup>4</sup>Department of Obstetrics, Center of Fetal Medicine, Shanghai, China, <sup>5</sup>Jiaxing Maternity and Children Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, Zhejiang, China, <sup>6</sup>School of Medicine, Tongji University, Shanghai, China

### KEYWORDS

fetal growth restriction (FGR), Olink proteomics platform, proximity extension assay (PEA), biomarkers, targeted proteomics analysis

## A Correction on

Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology

By Zhou X, Wang W, Chen L, Yang Y, Wei X, Zhou J, Sun K, Tang P, Sun X, Qin S and Sun L (2025). *Front. Immunol.* 16:1542034. doi: 10.3389/fimmu.2025.1542034

In the published article, there was an error in Figure 2B as published. Incorrect values were displayed on the pie chart. The corrected Figure 2 and its caption "Figure 2 Descriptive statistics of clinical information of FGR patients. (A) Gestational Week for Collection of Maternal Peripheral Blood for FGR patients and control samples; (B) Blood flow conditions for FGR patients; (C) Combined symptoms for FGR patients" appear below.

The original article has been updated.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



FIGURE 2

Descriptive statistics of clinical information of FGR patients. (A) Gestational Week for Collection of Maternal Peripheral Blood for FGR patients and control samples; (B) Blood flow conditions for FGR patients; (C) Combined symptoms for FGR patients.